Acadia Pharmaceuticals
ACAD
188 hedge funds and large institutions have $3.26B invested in Acadia Pharmaceuticals in 2015 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 83 increasing their positions, 61 reducing their positions, and 23 closing their positions.
36% more repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 61
9% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 23
0% more funds holding
Funds holding: 188 → 188 (0)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
21% less capital invested
Capital invested by funds: $4.12B → $3.26B (-$853M)
43% less call options, than puts
Call options by funds: $24.1M | Put options by funds: $42.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
+$52.5M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$45.9M |
| 3 |
FAM
Fred Alger Management
New York
|
+$35.1M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$27.7M |
| 5 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$25.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$59.2M |
| 2 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$58.3M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$30.9M |
| 4 |
BJCM
Blue Jay Capital Management
Los Angeles,
California
|
-$12.6M |
| 5 |
Capital World Investors
Los Angeles,
California
|
-$12.5M |
ACAD Hedge Fund Activity: Q3 2015 in Review
188 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q3 2015, worth a combined $3.26B — down 21% from $4.12B a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new ACAD positions and 23 closed out — a net gain of 2 holders — while 83 added to existing stakes and 61 trimmed.
The largest buyer was AllianceBernstein, adding an estimated $52.5M. The largest seller was Jennison Associates, cutting an estimated $59.2M.
- 188 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q3 2015, unchanged from Q2 2015.
- Funds reported $3.26B of Acadia Pharmaceuticals stock for Q3 2015, down 21% quarter-over-quarter.
- 25 funds opened new Acadia Pharmaceuticals positions in Q3 2015 and 23 closed out, a net change of +2 holders.
- The largest Acadia Pharmaceuticals buyer in Q3 2015 was AllianceBernstein, an estimated $52.5M added.
- The largest Acadia Pharmaceuticals seller in Q3 2015 was Jennison Associates, an estimated $59.2M sold.
Based on aggregated 13F filings for Q3 2015.